Chief Innovation and Technology Officer* · Aquestive Therapeutics, Inc. (AQST)

A. Mark Schobel

A named executive officer of Aquestive Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,257,284

Salary $367,500Stock awards $468,600

FY2023: $974,056

2nd of 3 named executive officers at Aquestive Therapeutics by FY2024 total.

3 named officers on file for Aquestive Therapeutics, FY2024

A. Mark Schobel’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aquestive Therapeutics’s whole pay program stands against its peers

  • Aquestive Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AQST→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A).

Free

Get A. Mark Schobel’s full pay file as a PDF — free

More than this page: up to 10 years of A. Mark Schobel’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

A. Mark Schobel compensation by year

Aquestive Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Aquestive Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2023FY2024
Salary$350,000$350,000$350,000$367,500
Bonus$0$0$0$0
Stock awards$56,115$1,792,029$320,500$468,600
Option awards$0$2,858,056$0$193,388
Non-equity incentive$367,500$291,291$275,625$262,500
Pension and deferred compensation$0$0$0$0
All other$21,590$2,284,286$27,931$1,965,296
Total$795,205$7,575,662$974,056$3,257,284

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aquestive Therapeutics, Inc. DEF 14A filed April 25, 2025, accession 0001140361-25-015781, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aquestive Therapeutics, Inc. filed document, accession 0001140361-25-015781. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

$795K
$7.6M
$974K
$3.3M
FY17
FY18
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU87,432$550,822—
RSU1,978$12,461—
Option206,810—$15.00
Option24,931—$16.46

Per the Outstanding Equity Awards at Fiscal Year-End table in Aquestive Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Aquestive Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Daniel BarberChief Executive Officer$4,181,472
A. Mark Schobel · this pageChief Innovation and Technology Officer*$3,257,284
Lori BraenderChief Legal Officer, Chief Compliance Officer and Corporate Secretary$1,821,025

The full Aquestive Therapeutics compensation record

free company brief

This page is one person within Aquestive Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aquestive Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

A. Mark Schobel's compensation dossier · One-time report. No refunds.